Through two world-class cancer centers – Columbia’s NCI-designated Herbert Irving Comprehensive Cancer Center and Weill Cornell Medicine’s Meyer Cancer Center, our team of physician-scientists are transforming care for cancer patients across a broad spectrum of malignant diseases and conditions. From pursuing novel laboratory research to better predict, diagnose and treat cancer, to conducting clinical trials of promising new therapies, our physicians provide personalized treatment plans to deliver optimal outcomes.
Featured Updates
Results from a new multi-center study, led by oncologists at NewYork-Presbyterian and Weill Cornell Medicine, has described for the first time a key biomarker – absolute lymphocyte count (ALC) – that has the potential to predict therapeutic response to chimeric antigen receptor (CAR) T-cell immunotherapy for patients with relapsed/refractory multiple myeloma. While this FDA-approved treatment is widely used, until now there has not been a way to predict whether B-cell maturation antigen (BCMA) CAR T-cell therapy would elicit a good response.
The Latest
Pediatric Neurology & Neurosurgery
Crossing Specialty Lines for Rare Genetic Neurocutaneous Conditions
